AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
This Study Will Investigate How Food and Age Effect the Way the Body Handles the AZD5069 Drug Given as a Oral Dose
- First Posted Date
- 2010-03-09
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT01083238
- Locations
- 🇬🇧
Research Site, London, United Kingdom
To Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2010-03-09
- Last Posted Date
- 2010-07-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 19
- Registration Number
- NCT01083212
- Locations
- 🇸🇪
Reserach Site, Linkoping, Sweden
🇸🇪Research Site, Uppsala, Sweden
Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus
- First Posted Date
- 2010-03-08
- Last Posted Date
- 2010-07-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT01082120
- Locations
- 🇺🇸
Research Site, Chula Vista, California, United States
Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Completed
- Conditions
- Non Small Cell Lung Cancer
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2011-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT01081496
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2011-11-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1077
- Registration Number
- NCT01081509
- Locations
- 🇭🇺
Research Site, Zirc, Hungary
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
Phase 2
Active, not recruiting
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 162
- Registration Number
- NCT01081951
- Locations
- 🇬🇧
Research Site, Edinburgh, United Kingdom
Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol Fumarate
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2010-03-02
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 176
- Registration Number
- NCT01078623
- Locations
- 🇷🇴
Research Site, Timisoara, Romania
Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats
Phase 2
Completed
- Conditions
- ProstatePancreaticBreastAdvanced TumoursOvarian
- Interventions
- First Posted Date
- 2010-03-02
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 298
- Registration Number
- NCT01078662
- Locations
- 🇸🇪
Research Site, Lund, Sweden
An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia
- First Posted Date
- 2010-03-02
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 315
- Registration Number
- NCT01078675
- Locations
- 🇳🇴
Research Site, Oslo, Norway
Evaluation of the Frequency of Limitation of Activity in Patients With Persistent Asthma
Completed
- Conditions
- Persistent Asthma
- First Posted Date
- 2010-03-02
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1942
- Registration Number
- NCT01078688
- Locations
- 🇫🇷
Research Site, Yerville, France